Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS Myeloma
NCT05050305Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of marizomib in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 5 years, Dose Limiting Toxicity up to 5 years and 2 more. Planned start Mar 2024; status: withdrawn.
02
Drugs
marizomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05050305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050305.